Free LIGHT Detection Assay for ARDS and Crohn's Severity Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions associated with elevated free LIGHT levels, such as COVID-19-related ARDS, Crohn's Disease, and immune dysregulation, are inadequate, and existing assays fail to accurately measure free LIGHT levels, which are crucial for understanding disease severity and progression.
Innovation Solution
Development of methods to detect and treat conditions associated with elevated free LIGHT levels using anti-LIGHT antibodies, including specific antibody sequences, and assays to measure free LIGHT levels accurately.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing assays are used to measure LIGHT levels, then measurement can be performed, but the measurement precision is insufficient to accurately detect free LIGHT levels
Solution Approach 1:
The patent employs a biotinylated anti-LIGHT antibody as an intermediary capturing agent in the assay system. This intermediary antibody specifically binds to free LIGHT in the sample, enabling selective capture and subsequent detection. The use of this intermediary mediator resolves the contradiction by providing a reliable method to accurately distinguish and measure only free LIGHT levels, thereby improving both measurement precision and disease severity assessment reliability
Solution Approach 2:
The patent utilizes streptavidin-conjugated fluorescent beads that exhibit enhanced fluorescent signal when bound to biotinylated anti-LIGHT antibody-LIGHT complexes. By changing the detection parameter from direct antibody binding to fluorescent signal intensity, the assay achieves superior measurement precision for free LIGHT levels, directly addressing the technical contradiction between measurement precision and assessment reliability
2Reliability
If conventional treatments are administered for conditions associated with elevated free LIGHT, then treatment can be provided, but the treatment effectiveness is insufficient to control disease progression
Solution Approach 1:
The patent describes anti-LIGHT antibodies that can be applied universally across multiple conditions associated with elevated free LIGHT levels, including Crohn's disease, acute lung injury, acute respiratory distress syndrome, and other inflammatory conditions. This multi-functional antibody therapy resolves the contradiction by providing a single adaptable treatment approach that can be customized through dosage and administration regimen adjustments to address different diseases, thereby achieving both reliable disease progression control and treatment adaptability
3Loss of information
If free LIGHT levels are not accurately measured, then assessment process is simple, but the information completeness for understanding disease severity is insufficient
Solution Approach 1:
The patent employs a segmented assay design that separates the measurement of free LIGHT from total LIGHT through sequential steps: first capturing free LIGHT with biotinylated anti-LIGHT antibody on fluorescent beads, then measuring the signal, and optionally subtracting from total LIGHT measurement to calculate bound LIGHT. This segmentation approach resolves the contradiction by breaking down the complex measurement task into manageable steps, where each step provides specific information, ultimately achieving complete disease severity information without overwhelming assay complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The methods effectively suppress T cell activation, reduce cytokine expression, and prevent conditions like ARDS and Crohn's Disease progression, offering a potential therapeutic approach for COVID-19 and other infections, and providing a more accurate assessment of disease severity.
Implementation Method 1
contacting the biological sample with at least one anti-LIGHT antibody; incubating the biological sample to allow the anti-LIGHT antibody to bind to free LIGHT
Data Source
AI summary
The present disclosure relates to methods of detecting free (active) LIGHT in biological samples to diagnose conditions associated with elevated free LIGHT, as well as to predict the effectiveness of anti-LIGHT therapies. The disclosure also relates to treating such conditions with anti-LIGHT antibodies. Conditions include acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), optionally wherein the ALI and ARDS are associated with viral infection, including coronavirus infection. Conditions also include Crohn's Disease or an inflammatory condition associated with Crohn's Disease.